





NANOTECHNOLOGY REVOLUTION: RESPIROCYTES AND ITS APPLICATION IN LIFE SCIENCES 
JAISWAL ARPITA1, THAKAR HINALI1, BEHERA ATANUKUMAR1, THAKKAR KRUNALI2, MESHRAM D.B.2 
1Department Of Pharmaceutics, Pioneer pharmacy degree college, Vadodara, 390019, Gujarat, India, 2Department of Quality assurance, 
Pioneer pharmacy degree college, Vadodara, 390019, Gujarat, India  E-mail:arpitajswl@gmail.com 
Received: 30 April 2013, Revised and Accepted: 2 May 2013 
ABSTRACT 
“Necessity is the mother of invention”. This necessity has made human now to stand at the verge of science. Nano technology is termed as 
application of science and technology at the nano level. From the many conditions which can do harm to the human body, one of the most 
fundamental and fast acting is a lack of perfusion of oxygen to the tissue. Insufficient oxygenation can be accoutred by problems with oxygen uptake 
in the lungs, problems with blood flow in the arteries due to obstruction or problems with oxygen transportation, as with anaemia. Heart attack is 
the death of part of the heart muscle due to its sudden loss of blood supply. Typically, the loss of blood supply is caused by a complete blockage of a 
coronary artery by a blood clot .To overcome this, respirocytes are proposed. An artificial nano-medical erythrocyte, or "respirocytes" --intended to 
duplicate all of the important functions of the red blood cell - provides treatment for anaemia, heart attack, choking, lung diseases, asphyxia, and 
other respiratory problems. These nano-robots, will be able to keep a patient's tissues safely oxygenated for up to about 4 hours (at maximum 
dosage) if their heart has stopped beating in case of a heart attack. The simplest possible design for an artificial respirocyte is a microscopic 
pressure vessel, spherical in shape for maximum compactness made from flawless diamond or sapphire constructed atom by atom. 
Keywords: nano technology, oxygen uptake, artificial red blood cells- respirocytes, pressure. 
INTRODUCTION:[1-4] 
Nanotechnology by definition is the study of manipulating matter on 
an atomic and molecular scale [1] This results in manmade 
molecules, typically 1-100 billionths of a metre [2], which can be 
manipulated in various ways to suit differing medical applications. 
The extremely small size of nanoparticles allows them to penetrate 
cells and interact with them [2] some techniques are currently in use 
today whilst others exist only in the imagination 
An artificial nanomedical erythrocyte, or “respirocyte” — intended 
to duplicate all of the important functions of the red blood cell — 
could serve as a universal blood substitute, preserve living tissue 
and provide treatment for anaemia, choking, lung diseases, asphyxia, 
and other respiratory problems.[3] 
The first artificially prepared red blood cells were fulfilling the 
following 3 major functions of red blood cells: (1) oxygen transport 
(2) carbon dioxide transport and (3) antioxidant functions. This 
method was in routine clinical use in South Africa and Russia. But, 
serious interest in this area did not start until the HIV contaminated 
donor blood crisis. Till then, there was no time to carry out the much 
required basic research. Firstly prepared Respirocytes are nano 
machines, very small mechanical devices designed to operate on the 
molecular level.  Each respirocyte is between 0.2 and 2 microns in 
diameter.[4] Respirocytes function as artificial prepared  red blood 
cells, which carries oxygen and carbon dioxide molecules 
throughout  the body. 
 
Function of red blood cells in body 
Red cells comprise at least 80% of all native cells in the human body. 
The biochemistry of respiratory gas transport in the blood is well 
understood. In brief, oxygen and carbon dioxide gas exchange are 
carried between the lungs and the other tissues, mostly within the 
red blood cells. Haemoglobin, the principal protein in the red blood 
cell, combines reversibly with oxygen, forming oxyhemoglobin. 
About 95% of the O2 is carried in this form, the rest being dissolved 
in the blood. At human body temperature, the haemoglobin in 1 litre 
of blood holds 200 cm3 of oxygen, 87 times more than plasma alone 
(2.3 cm3) can carry. 
Carbon dioxide also combines reversibly with haemoglobin; about 
25% of the CO2produced during cellular metabolism is carried in this 
form, with another 65% transported inside the red cells as 
bicarbonate ion and the remaining 10% dissolved in blood plasma.  
Respiratory gases are taken up or released by haemoglobin 
according to their local partial pressure. There is a reciprocal 
relation between haemoglobin’s affinity for oxygen and carbon 
dioxide. The relatively high level of O2 in the lungs aids the release of 
CO2, which is to be expired. The high CO2 level in other tissues aids 
the release of O2 for use by those tissues. 
Fig 1: Artificial red blood cells in blood stream 
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Respirocytes :A boon to life sciences [5-9] 
In the simplest case, continuous oxygen release throughout the body 
could be obtained. If slightly more sophisticated would be a system 
that releases gas in response to local O2 partial pressure. But these 
simple proposals fall short due to two reasons. 
First, if the device is discharged it will become useless. And the 
discharge time is too short. If there were no natural red cells around 
to help it out, it may create life threatening condition. The 
O2 contained in a 1 cm3 injection of 1000 atm microtanks would be 
exhausted in only 2 minutes. Second, throughout a capillary bed 
along with the existing red cell population, placement of a lot of 
sources of O2 emission were placed which would cause a serious 
problem. These extra emitters are functionally equivalent to RBCs 
whose CO2 transport and acid-buffering capabilities have been 
selectively disabled. Their addition to the blood causes higher 
CO2 tension and hydrogen ion concentration. These higher 
concentrations would rapidly lead to carbon dioxide toxicity and 
acidosis (hypercapnia), especially in anaemic, nonrespiratory, 
ischemic patients, as well as hyperoxic haemolysis and other 
complicated situations. 
The solution for the first problem of short duration is to 
continuously recharge the micro vessels with O2 gas at the lungs. 
Carbon dioxide toxicity can be prevented by providing extra tankage 
for CO2 transport and by designing a mechanism that actively loads 
the gas in the tissues and then unloads it at the lungs. 
 The size of the respirocytes must be designed in a manner so they 
have ready access to all tissues via blood vessels. They can’t be 
larger than human capillaries of average 8 microns in diameter but 
may be as small as 3.7 microns[5] – so narrow that natural red blood 
cells (7.8 micron x 2.6 micron biconcave disks) must fold in half so 
that it can be easily pass.[6] 
According to the study design, as radius decreases, surface area per 
unit volume increases rapidly. Thus smaller cells require more 
hollow tankage for a given amount of volume capacity. A careful 
study of operational requirements and minimum required sizes 
suggests that the optimum respirocyte diameter is about 1 micron. 
In the simplest case, oxygen release could be continuous throughout 
the body [7]. Slightly more sophisticated is a system responsive to 
local O2 partial pressure, with gas released either through a needle 
valve [8] controlled by a heme protein that changes conformation in 
response to hypoxia [9], or by diffusion via low pressure chamber 
into a densely packed aggregation of heme-like molecules trapped in 
an external fullerene cage porous to environmental gas and water 
molecules, or by molecular sorting rotors 
 
Fig 2: schematic representation of respirocytes 
 
PRESSURE VESSEL 
The main goal is transport of oxygen from the lungs to other body 
tissues, the simplest possible design contains microscopic pressure 
vessel, spherical in shape for higher compactness. 
Mostly proposals for durable respirocytes contains the strongest 
materials, like flawless diamond or sapphire, constructed atom by 
atom. A conservative applied stress in such structures would be as 
high about 100,000 atmospheres (atm) of pressure. But due to such 
high pressure, risk of rupture and explosive energy rises, so a 
standard 1000 atm of operating pressure appears optimum. This 
relatively low pressure will offer very high packing density of the gas 
molecules, while providing an extremely conservative 100-fold 
structural safety margin. 
Tank storage capacity can be calculated by van der waals equation 
that takes account of inter molecular forces due to finite sized tightly 
packed molecules= [nRT/(V-nB)] - [An2/V2], where P in atm, n in 
moles of gas, R = 8.206 x 10-5 m3-atm/mole-°K, T = 310 °K (human 
body temperature), V in m3, and constants A and B determined 
experimentally for each gas   . If comparison is done with natural red 
blood cells regarding storage of oxygen at an equivalent 0.51 atm 
pressure, of which only 0.13 atm is deliverable to tissues. 
MOLECULAR SORTING ROTORS [10-11] 
Transport of the gas molecules into, and out of, pressurized 
microvessels is the main requirement for the successful respirocyte. 
Molecular sorting rotors have been proposed  that would be ideal for 
this task .Each rotor is having binding sites called "pockets" along 
with the rim that are  exposed alternately to the blood plasma and 
inner chamber by the rotation of the disk. Each pocket selectively 
binds with a specific molecule when exposed to the plasma. Once the 
binding site exposed to the interior chamber, the bound molecules 
are forcefully ejected by rods. These devices can sort small 
molecules of 20 or fewer atoms at a rate of 106 molecules/sec and 
pump against head pressures up to 30,000 atm at an additional 
energy cost up to 10-19 joule/molecule. Rotors are fully reversible, so 
they can be used to load or unload gas storage tanks, depending 
upon the direction of rotor rotation. (It should be possible to recover 
most of the sorting energy by adding a generator subsystem, or by 
compressing one gas using energy derived largely from the 
decompression of the other [10] using differential gearing. Neither 
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alternative, which might reduce power consumption by a factor of 
~10-100, was pursued in the present design because the energy 
resource -- serum glucose -- appears plentiful.)Typical molecular 
concentrations in the blood for target molecules of interest (O2, CO2, 
N2 and glucose) are ~10-4, which should be sufficient to ensure at 
least 90% occupancy of rotor binding sites at the stated rotor speed 
[11]
 
Fig 3: Molecular sorting rotors 
 
MINIMUM THERAPEUTIC DOSE [11] 
The average male human body has 28.5 trillion red blood cells, each 
containing 270 million haemoglobin molecules. Each of them binds 
with four O2 molecules. However, since haemoglobin normally 
operates between 95% arterial blood flow and 70% venous blood 
flow, only 25% of stored oxygen is accessible to the tissues. 
In comparison with red blood cells, each respirocyte stores up to 
1.51 billion oxygen molecules, 100% of them are accessible to the 
tissues. To fulfil the complete requirement of human body, we have 
to supply 5.36 trillion devices. If respirocytes are administered via 
hypodermal injection or transfusion in a 50% aqueous colloidal 
suspension, this requires a standard ~5.61 cm3 therapeutic dose of 
activated suspension. One therapeutic dose can duplicate natural red 
cell function indefinitely if the patient is breathing. For the patients 
who have stopped breathing, it can supply all respiratory gas 
requirements from onboard storage alone for nearly 2 minutes. 
In normal case, the alveolar membrane of human lungs can transmit 
a maximum of 3.2x 1021 O2 molecules/sec across its surface, enough 
to fully load 42% of all therapeutic respirocytes during one transit 
time (5-10 sec [11]) of lung capillaries. Body blood circuit time is 
approx 60 sec in resting conditions, so only 17% of injected 
respirocytes are present in the lungs at any one time. And since 
respirocytes can establish higher osmotic gradients than natural red 
blood cells, the rate of alveolar oxygen diffusion should not limit 
reoxygenation of an exhausted therapeutic dose. 
POTENTIALITY OF RESPIROCYTES 
one of the potential benefits of nonmedical devices is their ability to 
extend natural human capabilities. Suppose you wanted to 
permanently maximize the oxygen-carrying capacity of your blood 
by infusing the largest possible number of respirocytes. The 
maximum safe augmentation dosage is probably about 1 litre of 50% 
respirocyte suspension, which puts 954 trillion devices into your 
bloodstream. You could then hold your breath for 3.8 hours, at the 
normal resting metabolic rate. At the maximum human metabolic 
rate, something like a continuous Olympic-class 50-meter dash 
exertion level, you could go for a full 12 minutes without taking a 
breath. Afterwards, your entire capacity is recharged by 
hyperventilating for just 8 minutes – then you’re ready to go again. 
SAFETY REGARDING USE OF RESPIROCYTES [12-13] 
Assumptions regarding malfunctions will detect simple failure 
modes like jammed rotor banks, plugged exhaust ports, and gas 
leaks, either switching to backup systems or using those backups to 
safely place the device into a fail-safe dormant mode pending 
removal by filtration. Respirocytes are extremely reliable as a simple 
analysis of likely radiation damage suggests that the average 
respirocyte should last about 20 years before failing. 
 If other malfunctions like all the glucose powerplant get jammed or 
refuse o turn off while the respirocyte is in the bloodstream, its 
temperature will not rise at all. That’s because the 7.3 picowatts of 
continuous thermal energy which is generated by device is easily 
absorbed by the huge aqueous heat sink, which has a bountiful heat 
capacity.  
In the worst case, it leads to complete structural failure of a 
respirocyte in vivo. Patients will suffer a high-speed head-on 
automobile collision experience instantaneous accelerations of 100-
10,000 g’s (gravity is 1 g), [12] but due to the presence of spherical 
diamonded shell will resist accelerations up to 108-1010 g’s. Crushing 
respirocyte-impregnated human tissue in a hydraulic press is 
unlikely to destroy any devices, as they will simply slide out of the 
way. The same logic applies to gunshot wounds, knife accidents that 
cut deep to hard bone, and blunt object blows to the skull. [13] 
Indeed, the other respirocyte explosion scenario is dental grinding. 
As the tooth enamel is the hardest natural substance in the human 
body, and a patient with an oral lesion could spread respirocyte-
impregnated blood over the teeth. Single respirocyte explosions may 
not be detectable; several thousand going off at once might 
produce“fizziness” in the mouth. Simultaneously crushing 20 million 
respirocytes (the count in a 0.5-mm droplet of augmentation-dose 
blood) could produce a maximum jaw-speed (0.1 m/sec) explosive 
impulse. 
Collisions with respirocytes or their spinning sorting rotors are 
unlikely to cause serious physical damage to other cells in the 
bloodstream such as platelets, white cells, or natural red cells, nor 
will collisions injure blood vessel walls. While definitive 
experimental data is not yet available, preliminary tests show 
diamondoid surfaces to be very biocompatible, unlikely to draw a 
major response from leukocytes, the immune system, or other 
natural body defences. 
APPLICATIONS: 
The artificial respirocyte is a  nanotechnological device whose 
primary applications include transfusable blood substitution; 
treatment for anaemia, perinatal and neonatal disorders, and a 
variety of lung diseases and conditions; contribution to the success 
of certain aggressive cardiovascular and neurovascular procedures, 
tumour therapies and diagnostics; prevention of asphyxia; 
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maintenance of artificial breathing in adverse environments; and a 
variety of sports, veterinary, battlefield and other applications. 
Transfusion of blood and perfusion of organs [14]  
Respirocytes can be used as the active oxygen-carrying component 
of a universally transfusable blood substitute which is free of disease 
vectors such as hepatitis, venereal disease, malarial parasites or 
AIDS, storable indefinitely and readily available and doesn’t require 
any cross-matching.[14]. In current scenario, organs must be 
transplanted soon after harvest; respirocytes could be used as a 
long-duration perfusant to preserve living tissue, especially at low 
temperature, for grafts (kidney, marrow, liver and skin) and organ 
transplantation. 
 Treatment of Anaemic conditions [15] 
Oxygenating respirocytes offer complete or partial symptomatic 
treatment for virtually all forms of anaemia, including acute anaemia 
which is caused by a sudden loss of blood after any injury or surgical 
intervention; secondary anaemia caused by bleeding typhoid, 
duodenal or gastric ulcers; chronic, gradual, or post-hemorrhagic 
anaemia from bleeding gastric ulcers (including ulcers caused by 
hookworm),excessive menstrual bleeding, or battle injurie, 
haemorrhoids  in war zones; hereditary anaemia including 
haemophilia, leptocytosis and sicklemia, thalassemia, haemolytic 
jaundice and congenital methemoglobinemia; chlorosis and 
hypochromic anemia, endocrine deficiency anaemia, pernicious and 
other nutritional anemias; anaemia resulting from infectious 
diseases including rheumatism, scarlet fever, tuberculosis, syphilis, 
chronic renal failure and cancer, or from haemoglobin poisoning 
such as by carbon monoxide inhalation; haemolytic anemias 
including chemical haemolysis (including malarial, snake bite, etc.), 
paroxysmal hemoglobinuria, and chronic haemolytic anaemia from 
hypersplenism due to cirrhosis of the liver; leukaemia and other 
idiopathic or toxic aplastic anemias caused by chemicals, radiation, 
or various antimetabolic agents; and diseases involving excessive 
red cell production such as polycythemia.[15] 
Fetal abnormalities and Child-Related Disorders 
Respirocytes may be useful in prenatal medicine, as for example 
infusions of device suspension to treat erythroblastosis fetalis, 
neonatal haemolytic disease, or in utero asphyxia from partial 
detachment of the placenta or maternal hypoxia, to restore the 
oxygen-carrying ability of fetal blood. Asphyxia neonatorum, as from 
umbilical cord compression during childbirth, may fatally deprive 
the infant of oxygen; prenatal respirocyte treatment could be 
preventative. Many cases of Sudden Infant Death Syndrome (SIDS) 
or crib death, the leading cause of neonatal death between 1 week 
and 1 year of age, and also for respiratory distress syndrome involve 
recurrent oxygen deprivation or abnormalities in the automatic 
control of breathing, both of which could be delethalized using a 
therapeutic dose of red cell devices. Respirocytes could also aid in 
the treatment of childhood afflictions such as whooping cough, cystic 
fibrosis, rheumatic heart disease and rheumatic fever, congenital 
heart disorders and laryngotracheobronchitis (croup). 
 Respiratory tract and breathing Disorders [16-17] 
Current treatments for a variety of respiratory tract diseases, 
including pneumonia, bronchopneumonia and pleuropneumonia; 
pneumoconiosis including asbestosis, silicosis and berylliosis; 
emphysema, emphysema, abscess, pulmonary enema and pleurisy; 
epidemic pleurodynia; diaphragm diseases such as diaphragmatic 
hernia, tetanus, and hiccups; blood flooding in lungs (hemoptysis, 
tuberculosis, chronic histoplasmosis, and bronchial tube rupture); 
bronchitis and bronchiectasis; atelectasis and pneumothorax; 
chronic obstructive lung disease; arterial chest aneurysm; influenza, 
dyspneas, and even laryngitis, snoring, pharyngitis, hay fever and 
colds could be improved using respirocytes to reduce the need for 
strong, regular breathing. 
The devices can be used as  an effective long-term drug-free 
symptomatic treatment for asthma, and can also  assist in the 
treatment of hemotoxic  and neurotoxic , snake bites; hypoxia, stress 
polycythemia and lung disorders resulting from cigarette smoking 
and alcoholism; neck goiter and cancer of the lungs, pharynx, or 
thyroid; pericarditis, coronary thrombosis, hypertension, and even 
cardiac neurosis; obesity, quinsy, botulism, diphtheria, tertiary 
syphilis, amyotrophic lateral sclerosis, uremia, coccidioidomycosis 
(valley fever), and anaphylactic shock; and Alzheimer's disease 
where hypoxia is speeding the development of the condition. 
Respirocytes could also be used to treat conditions of low oxygen 
availability in nerve tissue, as occurs in advanced atherosclerotic 
narrowing of arteries, strokes, diseased or injured reticular 
formation in the medulla oblongata (controlling autonomic 
respiration), birth traumas leading to cerebral palsy, and low blood-
flow conditions seen in most organs of people as they age. Even 
poliomyelitis, which still occurs in unvaccinated Third World 
populations, could be treated with respirocytes and a diaphragmatic 
pacemaker. 
Cardiovascular and Neurovascular diseases [17-21] 
Respirocytes perfusion could be useful in maintaining tissue 
oxygenation during anaesthesia, coronary angioplasty, organ 
transplantation, Siamese-twin separation, other aggressive heart 
and brain surgical procedures [17-18], in postsurgical cardiac 
function recovery, and in cardiopulmonary bypass solutions [19]. 
The device could help prevent gangrene and cyanosis, for example, 
during treatment of Reynaud’s Disease, a condition in which spasms 
in the superficial blood vessels of the extremities cause fingers and 
toes to become cyanotic, then white and numb. Therapeutic 
respirocytes dosages can delay brain ischemia under conditions of 
heart or lung failure, and might be useful in treating senility, which 
has apparently been temporarily reversed in patients treated with 
hyperbaric oxygen [20-21] 
 Treatment of tumour and Diagnostics [22-24] 
Cancer patients are usually anaemic. X-rays and many 
chemotherapeutic agents require oxygen to be maximally cytoxic, so 
boosting systemic oxygenation levels into the normal range using 
respirocytes might improve prognosis and treatment outcome [22-
23]. Fluorocarbon emulsions have been used to probe tissue oxygen 
tension ;similarly, respirocytes could be used as reporter devices to 
map a patient's whole-body blood pressure or oxygenation profile, 
storing direct sensor data in each computer along with positional 
information recorded from a network of precisely positioned 
acoustic transponders, to be later retrieved by device filtration and 
data reconstruction . A similar network of acoustic transmitters, 
making possible respirocytes auto triangulation hence precise 
internal positional knowledge, could allow preferential super 
oxygenation of specific tissues, enhancing treatment effectiveness. 
[24] 
Asphyxia conditions [25-26] 
Respirocytes make breathing possible in oxygen-poor environments 
or in cases where normal breathing is physically impossible. Prompt 
injection with a therapeutic dose, or advance infusion with an 
augmentation dose, could greatly reduce the number of choking 
deaths and the use of emergency tracheotomise, artificial respiration 
in first aid, and mechanical ventilators. The device provides an 
excellent prophylactic treatment for most forms of asphyxia, 
including drowning, strangling, electric shock (respirocytes are 
purely mechanical), nerve-blocking paralytic agents, carbon 
monoxide poisoning, underwater rescue operations, smoke 
inhalation or fire fighting activities, anaesthetic/barbiturate 
overdose, confinement in airtight spaces like closets, bank vaults, 
mines, submarines), and obstruction of breathing by a chunk of meat 
or a plug of chewing tobacco lodged in the larynx, by inhalation of 
vomitus, or by a plastic bag pulled over the head of a child. 
Respirocytes augment the normal physiological responses to 
hypoxia, which may be mediated by pulmonary neuroepithelial 
oxygen sensors in the airway mucosa of human and animal lungs 
[25] 
A design alternative to augmentation infusions is a therapeutic 
population of respirocytes that loads and unloads at an artificial 
nano lung, implanted in the chest, which exchanges gases directly 
with the natural lungs or with exogenous gas supplies. (An 
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intravascular oxygenator using a bundle of hollow fibre membranes 
inserted into the vena caval bloodstream (which functions as an 
"artificial lung") is in clinical trials [26] 
Underwater Breathing 
Respirocytes could serve as an in vivo SCUBA (Self-Contained 
Underwater Breathing Apparatus) device. With an augmentation 
dose or nano lung, the diver holds his breath for 0.2-4 hours, goes 
about his business underwater, then surfaces, hyperventilates for 6-
12 minutes to recharge, and returns to work below. (Similar 
considerations apply in space exploration scenarios.) 
The same device can be used for temporary relief from nitrogen 
narcosis while diving, since N2 has an aesthetics effect beyond 100 
feet of depth. 
Direct water-breathing, even with the help of respirocytes, is 
problematic for several reasons: (1) Seawater contains at most one-
thirtieth of the oxygen per lungful as air, so a person must breathe at 
least 30 times more lungful of water than air to absorb the same 
volume of respiratory oxygen; lungs full of water weigh nearly three 
times more than lungs full of air, so a person could hyperventilate 
water only about one-third as fast as the same volume of air. As a 
result, a water-breathing human can absorb at most 1%-10% of the 
oxygen needed to sustain life and physical activity. (2) Deep bodies 
of water may have low oxygen concentrations because oxygen is 
only slowly distributed by diffusion; in swamps or below the 
thermocline of lakes, circulation is poor and oxygen concentrations 
are low, a situation aggravated by the presence of any oxygen-
consuming bottom dwellers or by oxidative processes involving 
bottom detritus, pollution, or algal growth. (3) Both the diving reflex 
and the presence of fluids in the larynx inhibit respiration and cause 
closure of the glottis, and inhaled waterborne micro flora and micro 
fauna such as protozoa, diatoms, dinoflagellates, zooplankton and 
larvae could establish (harmful) residence in lung tissue. 
Other Application area[27-36] 
Respirocytes also permit major new sports records to be achieved, 
because the devices can deliver oxygen to muscle tissues faster than 
the lungs can provide, for the duration of the sporting event. This 
would be especially useful in running, swimming, and other 
endurance-oriented events, and in competitive sports such as 
basketball, football and soccer where extended periods of sustained 
maximum exertion are required. Blood doping [27] and 
erythropoietin injection [28-30], though illegal, are common among 
athletes to increase tissue oxygenation, hence performance.) Aerobic 
capacity in men declines with age, from ~6.9 kg O2/day at age 25 to 
~3.7 kg O2/day at age 75 [31], so respirocytes could improve 
geriatric sports participation. 
Hyperbaric oxygenation by respirocytes could helps in treatment of 
various anaerobic and aerobic [32] infections such as clostridia 
myonecrosis, chronic refractory osteomyelitis, and necrotizing soft 
tissue infections including cutaneous ulcers, and could assist in burn 
recovery by reducing fluid requirements, improving 
microcirculation, and reducing the need for grafting [33]. 
Artificial blood substitutes may also use in veterinary medicine [34-
35], especially in cases of vehicular trauma and renal failure where 
transfusions are required, and in battlefield applications demanding 
blood replacement or personnel performance enhancement. 
Swallowed in pill form, respirocytes could be an effective, though 
temporary, cure for flatulence, which gas is largely swallowed air 
and CO2 generated by fermentation in the stomach. With suitable 
modifications, respirocyte technology could provide a precisely 
metered ingestible or injectable drug delivery system, or could assist 
in the management of serum glycerides, fatty acids or lipoproteins, 
diabetic ketosis and gestational diabetes, and other dietary 
conditions. [36] 
CONCLUSION: 
The present paper represents a simple artificial erythrocyte nano 
device. Such artificial blood cells carry function similar to natural red 
blood cells. It includes transport of oxygen and elimination of carbon 
dioxide. The artificial respirocyte can deliver 236 times more oxygen 
to the tissues per unit volume than natural red blood cells, and 
facilitates a similar advantage in carbon dioxide transport. 
The respirocyte is constructed of tough diamond like material, 
having a variety of chemical, thermal and pressure sensors, also 
having nano computer which enables the device to display many 
complex responses, that can be remotely programmed by external  
signals to modify existing or to install new protocols, and draws 
power from natural serum glucose supplies, thus is capable of 
operating intelligently and virtually indefinitely, unlike red blood 
cells which have a natural lifespan of 4 months. 
Such respirocytes found application in various field like artificial 
breathing, under water breathing and in asphyxia condition. It is also 
helpful in various disorders associated with respiration, 
cardiovascular, neurological, etc.It also serves a diagnostic purpose. 
Such device can’t be executed today. However today it’s a world of 
advancement and invention, future technologies in molecular 
machines permits formation of such artificial respirocytes which can 
be applied in advanced medical system. 
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